Glioma
Drug research and approvals for glioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 575 studies of glioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 29 drug trials for it since 2013, FDA has 12 approved and 171 open orphan designations naming it, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 575
- Trials authorized in Canada: 29
- FDA orphan approvals: 12
- EU medicines: 9
Recruiting Now
Newest start dates first, of 575 recruiting on ClinicalTrials.gov ↗- Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and…NCT06485908 · Phase 1 / Phase 2 · Assistance Publique Hopitaux De Marseille · starts Feb 1, 2032
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment…NCT07703436 · Phase 2 · Nuvation Bio Inc. · starts Mar 1, 2027
- Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in BrazilNCT07789678 · Not reported · Latin American Cooperative Oncology Group · starts Feb 1, 2027
- Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed GlioblastomaNCT07884344 · Early Phase 1 · Macarena De La Fuente, MD · starts Dec 1, 2026
- Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With…NCT07796061 · Phase 1 · Children's National Research Institute · starts Dec 1, 2026
- Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGGNCT05555550 · Early Phase 1 · Children's Hospital of Philadelphia · starts Nov 29, 2026
- Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced SonicationNCT07754006 · Phase 1 · Gustave Roussy, Cancer Campus, Grand Paris · starts Nov 1, 2026
- TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly GliomaNCT07862647 · Phase 1 · Alpheus Medical, Inc. · starts Oct 29, 2026
- A Phase I Clinical Study of YN003 in the Treatment of GliomaNCT07929909 · Phase 1 · Beijing Inno Medicine Co., Ltd. · starts Oct 27, 2026
- Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma PatientsNCT07775534 · Not applicable · City of Hope Medical Center · starts Oct 23, 2026
Trials Authorized in Canada
The 10 newest of 29; search them all in Canada trials| Aug 20, 2026 | A phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1…SAFUSIDENIB (AB-218, DS-1001B) | Nuvation Bio | Pending |
| Jul 3, 2026 | Microscopic mapping of gadolinium in human glioma to define the tissue basis of radiographic enhancementGADOBUTROL | MCGILL UNIVERSITY | Pending |
| Mar 24, 2026 | A phase II trial of act001 in children and adolescents with diffuse intrinsic pontine gliomas and h3k27-altered high grade gliomasACT001 | COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT) | Ongoing |
| Jun 4, 2025 | A phase 1/2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the…MIRDAMETINIB / VINBLASTINE | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE | Ongoing |
| Mar 4, 2025 | Phase 2 study of ribociclib-containing post-radiotherapy combinations in pediatric and young adult patients newly diagnosed with high-grade glioma (hgg),…EVEROLIMUS / RIBOCICLIB | COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT) | Pending |
| Feb 28, 2025 | A phase II study evaluating the safety, efficacy, and intracranial activity of tarlatamab in recurrent/refractory gliomas with idh mutation (targid)IMDELLTRA | UNIVERSITY HEALTH NETWORK | Ongoing |
| Aug 20, 2024 | Assessment of safety and feasibility of fus next generation dome helmet mediated blood-brain barrier disruption for the treatment of high-grade glioma in…PERFLUTREN (PERFLUOROPROPANE) | SUNNYBROOK RESEARCH INSTITUTE | Ongoing |
| Jun 13, 2024 | U-r-immune glioma (ca209-1245): a pilot study investigating upfront adaptive immunotherapy approach in children, adolescent and young adult (caya) patients…OPDIVO | THE HOSPITAL FOR SICK CHILDREN | Ongoing |
| Dec 13, 2023 | A pilot study to investigate safety and efficacy of weekly combination of intravenous vinblastine with oral type ii raf inhibitor tovorafenib in pediatric…TOVORAFENIB (DAY 101) | THE HOSPITAL FOR SICK CHILDREN | Ongoing |
| Feb 28, 2023 | Onc201 for the treatment of newly diagnosed h3 k27m-mutant diffuse glioma following completion of radiotherapy: a randomized, double-blind, placebo-controlled,…DORDAVIPRONE (ONC201) | Chimerix | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 183| Sep 11, 2026 | Pixclarafor use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in… | Telix Pharmaceuticals Limited (Telix) | Approved |
| Aug 6, 2025 | Modeysotreatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with… | Chimerix, Inc. | Approved |
| Aug 6, 2024 | Voranigotreatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate… | Servier Pharmaceuticals LLC | Approved |
| Apr 23, 2024 | Ojemdatreatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or… | Day One Biopharmaceuticals, Inc. | Approved |
| Mar 16, 2023 | Mekinistin combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF… | Novartis Pharmaceuticals Corporation | Approved |
| Mar 16, 2023 | Tafinlarin combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF… | Novartis Pharmaceuticals Corporation | Approved |
| Jun 6, 2017 | GleolanOptical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as… | NX Development Corporation | Approved |
| May 5, 2009 | AvastinTreatment of glioblastoma with progressive disease following prior therapy | Genentech, Inc. | Approved |
| Mar 15, 2005 | TemodarTreatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment | Schering-Plough Research Institute | Approved |
| Feb 25, 2003 | GliadelExpanding the indication to include patients with malignant glioma undergoing primary surgical resection. | Guilford Pharmaceuticals, Inc. | Approved |
| Aug 11, 1999 | TemodarTreatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease… | Schering-Plough Research Institute | Approved |
| Sep 23, 1996 | GliadelAs an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated | Guilford Pharmaceuticals, Inc. | Approved |
| Sep 21, 2026 | Allogeneic gamma delta T cells modified by messenger RNA…treatment of malignant glioma | Ever Supreme Bio Technology Co., Ltd. | Designated |
| Aug 27, 2026 | reversible, adenosine triphosphate (ATP) competitive…treatment of malignant glioma | Biomed Valley Discoveries Inc. | Designated |
| Jul 13, 2026 | co-packaged combination of perillyl alcohol and…treatment of the malignant glioma | Curatio Therapeutics, LLC | Designated |
Medicines Authorised in the EU
Newest first| Apr 20, 2026 | Ojemdatovorafenib · orphan | Ipsen Pharma | EMA ↗ |
| Jan 5, 2024 | Spexotrastrametinib · orphan | Novartis Europharm Limited | EMA ↗ |
| Nov 15, 2023 | Finleedabrafenib · orphan | Novartis Europharm Limited | EMA ↗ |
| Jul 13, 2011 | Temozolomide Suntemozolomide · generic | Sun Pharmaceutical Industries Europe B.V. | EMA ↗ |
| Mar 15, 2010 | Temozolomide Accordtemozolomide · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 28, 2010 | Temozolomide Tevatemozolomide · generic | Teva B.V. | EMA ↗ |
| Jan 25, 2010 | Temomedactemozolomide · generic | medac Gesellschaft für klinische Spezialpräparate mbH | EMA ↗ |
| Sep 7, 2007 | Gliolan5-aminolevulinic acid hydrochloride | Photonamic GmbH & Co. KG | EMA ↗ |
| Jan 26, 1999 | Temodaltemozolomide | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA